Biotronik announced that it entered into a strategic distribution agreement with CardioFocus for pulsed field ablation (PFA) technology.
The companies agreed to make Biotronik the exclusive distributor of the Centauri PFA system in select European countries.
Centauri, CardioFocus’ open-platform PFA system, supports focal contact force catheter workflows. It leverages a custom monopolar waveform designed to achieve transmural lesions while eliminating microbubbles and muscle stimulation. The system enables durable PFA lesions while enhancing procedural efficiency, safety and patient outcomes.
“We are proud to collaborate with CardioFocus to expand the reach of the Centauri System in key European markets. As pulsed field ablation evolves, hospitals increasingly need solutions that combine strong clinical performance with flexibility. This collaboration reflects our ongoing commitment to advancing innovation in electrophysiology and supporting physicians in improving patient outcomes,” said Dr. Andreas Hecker, President CRM/EP at Biotronik.
The next-generation focal PFA system offers a controllable, versatile solution for cardiac ablation to treat paroxysmal AFib.
“We are thrilled to partner with a company as well-established and clinically trusted as Biotronik to bring our technology to more physicians and patients across Europe,” said Steve Ogilvie, CEO of CardioFocus. “Biotronik’s deep electrophysiology expertise, expansive global presence, and commitment to physician training make them the ideal partner to support the next phase of Centauri’s growth.”
